⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10458342 | 0.69 | — | — | |
| Hydrochloric Acid SCHEMBL28462716 | 0.67 | — | — | |
| SCHEMBL20016668 | 0.67 | — | — | |
| SCHEMBL9463592 | 0.67 | — | — | |
| SCHEMBL800658 | 0.67 | — | — | |
| SCHEMBL29261029 | 0.65 | — | — | |
| SCHEMBL25082459 | 0.64 | — | — | |
| SCHEMBL8740950 | 0.64 | — | — | |
| SCHEMBL22301080 | 0.64 | — | — | |
| SCHEMBL13103927 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9764039-B2 | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use | SUTRO BIOPHARMA, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-9738724-B2 | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use | SUTRO BIOPHARMA, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-9732161-B2 | Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use | SUTRO BIOPHARMA, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20170226178-A1 | THERAPEUTIC USES OF MODIFIED RELAXIN POLYPEPTIDES | AMBRX, INC. | 2017-08-10 | — | — | US | disclosed |
| US-9637441-B2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | AMBRX, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-20170096463-A1 | Modified FGF-21 Polypeptides and Their Uses | AMBRX, INC. | 2017-04-06 | — | — | US | disclosed |
| US-9567386-B2 | Therapeutic uses of modified relaxin polypeptides | AMBRX, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-20170035897-A1 | Modified Relaxin Polypeptides and Their Uses | AMBRX, INC. | 2017-02-09 | — | — | US | disclosed |
| US-9517273-B2 | Methods of treatment using modified FGF-21 polypeptides comprising non-naturally occurring amino acids | AMBRX, INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-9452222-B2 | Nucleic acids encoding modified relaxin polypeptides | AMBRX, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20080182968-A1 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080182969-A1 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080177027-A1 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080153979-A1 | non-natural amino acids are selected from amino acids having protected or masked carbonyl, dicarbonyl, hydroxylamine, or oxime side chains, and amino acid attached to a polyoxyethylene glycol, acrylic polymers or natural polymer; therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC. (US) | 2008-06-26 | — | — | US | disclosed |
| US-20080139793-A1 | Accelerants for the Modification of Non-Natural Amino Acids and Non-Natural Amino Acid Polypeptides | AMBRX, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| US-7385028-B2 | Modified non-natural amino acid polypeptides typically include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group; therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC (US) | 2008-06-10 | — | — | US | disclosed |
| US-20080125574-A1 | Blood plasma protein for use as carrier medical therapeutics | AMBRX, INC. (US) | 2008-05-29 | — | — | US | disclosed |
| US-20080107680-A1 | Modified Human Growth Hormone | AMBRX, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080102124-A1 | Modified Human Growth Hormone | AMBRX, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-7332571-B2 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC. (US) | 2008-02-19 | — | — | US | disclosed |